Premyelinating Oligodendrocytes in Chronic Lesions of Multiple Sclerosis
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Background Multiple sclerosis is an inflammatory disease of the central nervous system that destroys myelin, oligodendrocytes, and axons. Since most of the lesions of multiple sclerosis are not remyelinated, enhancement of remyelination is a possible therapeutic strategy that could perhaps be achieved with the transplantation of oligodendrocyte-producing cells into the lesions. We investigated the frequency distribution and configuration of oligodendrocytes in chronic lesions of multiple sclerosis to determine whether these factors limit remyelination. Methods Forty-eight chronic lesions obtained at autopsy from 10 patients with multiple sclerosis were examined immunocytochemically for oligodendrocytes and oligodendrocyte progenitor cells. Using confocal microscopy, we examined the three-dimensional relations between axons and the processes of premyelinating oligodendrocytes. Results Thirty-four of the 48 chronic lesions of multiple sclerosis contained oligodendrocytes with multiple extended processes that associated with demyelinated axons but failed to myelinate them. These axons were dystrophic and contained multiple swellings. In some regions, the densities of premyelinating oligodendrocytes (25 per square millimeter of tissue) were similar to those in the developing rodent brain (23 per square millimeter). In the patients with disease of long duration (more than 20 years), there were fewer lesions with premyelinating oligodendrocytes (P Conclusions Premyelinating oligode…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The efficacy of remyelination has been shown to depend on multiple factors such as, age, disease duration and lesion location.”
From BCAS1-positive oligodendrocytes enable efficient cortical remyelination in multiple sclerosis (2025) · cites this paper as [12]
In the citing paper
“The long‐term consequence of demyelination in the CNS is axonal damage and neurodegeneration (Chang et al. 2002) in both white and gray matter lesions, leading to progressive disease.”
From Depletion of Microglia Increases Cortical Oligodendrocyte Density During Remyelination (2026) · cites this paper as Chang et al. 2002
In the citing paper
“In MS lesions, OPCs are recruited but fail to differentiate into myelinating OLs, suggesting that remyelination is blocked at the differentiation and remyelination stage rather than during OPC recruitment (Chang et al., 2002; Kuhlmann et al., 2008; Wolswijk, 1998).”
From miR-219 Cooperates with miR-338 in Myelination and Promotes Myelin Repair in the CNS (2017) · cites this paper as Chang et al., 2002
In the citing paper
“In MS lesions, OPCs are recruited but fail to differentiate into myelinating OLs, suggesting that remyelination is blocked at the differentiation and remyelination stage rather than during OPC recruitment (Chang et al., 2002; Kuhlmann et al., 2008; Wolswijk, 1998).”
From miR-219 Cooperates with miR-338 in Myelination and Promotes Myelin Repair in the CNS (2017) · cites this paper as Chang et al., 2002
In the citing paper
“Furthermore, oligodendrocyte progenitor cells (OPCs) are a population of adult stem cells responsible for mediating CNS myelin repair in demyelinating conditions such as MS [113,114].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [114]
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Self-citationNoseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
Raff, M. C., Miller, R. H., & Noble, M. (1983) · Nature · doi:10.1038/303390a0 · Cited by 2,030
Axonal damage in acute multiple sclerosis lesions
Ferguson, B. (1997) · Brain · doi:10.1093/brain/120.3.393 · Cited by 1,532
WEINSHENKER, B. G., BASS, B., RICE, G. P. A., NOSEWORTHY, J., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C. (1989) · Brain · doi:10.1093/brain/112.1.133 · Cited by 1,452
Cell death and control of cell survival in the oligodendrocyte lineage
Barres, B. A., Hart, I. K., Coles, H. S. R., Burne, J. F., Voyvodic, J. T., Richardson, W. D., & Raff, M. C. (1992) · Cell · doi:10.1016/0092-8674(92)90531-g · Cited by 1,345
Multiple Sclerosis and Chronic Autoimmune Encephalomyelitis
Kornek, B., Storch, M. K., Weissert, R., Wallstroem, E., Stefferl, A., Olsson, T., Linington, C., Schmidbauer, M., & Lassmann, H. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64537-3 · Cited by 921
The oligodendrocyte and its many cellular processes
PFEIFFER, S., WARRINGTON, A., & BANSAL, R. (1993) · Trends in Cell Biology · doi:10.1016/0962-8924(93)90213-k · Cited by 737
NG2-Positive Oligodendrocyte Progenitor Cells in Adult Human Brain and Multiple Sclerosis Lesions
Chang, A., Nishiyama, A., Peterson, J., Prineas, J., & Trapp, B. D. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-17-06404.2000 · Cited by 712
Self-citation
Research works printed but not linked: 2
- 10.1056/nejm199801293380610 · doi:10.1056/nejm199801293380610 · Paper page
- Prineas JW, 1989, Lab Invest, 61, 489
Cited by
Items 101–200 of 1,000
The neural androgen receptor: a therapeutic target for myelin repair in chronic demyelination
Hussain, R., Ghoumari, A. M., Bielecki, B., Steibel, J., Boehm, N., Liere, P., Macklin, W. B., Kumar, N., Habert, R., Mhaouty-Kodja, S., et al. (2013) · Brain · doi:10.1093/brain/aws284 · Cited by 175
“Remyelination involves the proliferation and maturation of oligodendrocyte precursor cells The remyelination of axons requires the generation of new oligodendrocytes from oligodendrocyte precursor cells (Chang et al., 2002; Franklin and ffrench-Constant, 2008).”
BackgroundEnhancing remyelination in disease--can we wrap it up?
Kotter, M. R., Stadelmann, C., & Hartung, H.-P. (2011) · Brain · doi:10.1093/brain/awr014 · Cited by 181
“However, despite expression of Sema3A in experimental as well as in multiple sclerosis lesions (Williams et al., 2007; Syed et al., 2010) the recruitment of oligodendrocyte precursor cells is not generally deficient (Wolswijk, 1998, 2000; Chang et al., 2000, 2002; Kuhlmann et al., 2008).”
BackgroundIntegrins direct Src family kinases to regulate distinct phases of oligodendrocyte development
Colognato, H., Ramachandrappa, S., Olsen, I. M., & ffrench-Constant, C. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200404076 · Cited by 177
“Therefore, a prediction from the current study is that reducing Csk expression or activity may also help trigger myelination in the stalled preoligodendrocytes that have been observed in demyelinated multiple sclerosis lesions (Chang et al., 2002).”
BackgroundAn ‘oligarchy’ rules neural development
Rowitch, D. H., Lu, Q. R., Kessaris, N., & Richardson, W. D. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(02)02201-4 · Cited by 181
Gain of Olig2 function in oligodendrocyte progenitors promotes remyelination
Wegener, A., Deboux, C., Bachelin, C., Frah, M., Kerninon, C., Seilhean, D., Weider, M., Wegner, M., & Nait-Oumesmar, B. (2015) · Brain · doi:10.1093/brain/awu375 · Cited by 169
“Furthermore, it has been shown that despite the presence of endogenous OPCs in chronic lesions of multiple sclerosis (Wolswijk, 1998; Chang et al., 2002), they often fail to remyelinate axons, suggesting a differentiation failure (Arnett et al., 2004; Kuhlmann et al., 2008).”
BackgroundSeparated at birth? The functional and molecular divergence of OLIG1 and OLIG2
Meijer, D. H., Kane, M. F., Mehta, S., Liu, H., Harrington, E., Taylor, C. M., Stiles, C. D., & Rowitch, D. H. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3386 · Cited by 172
Kremer, D., Schichel, T., Förster, M., Tzekova, N., Bernard, C., van der Valk, P., van Horssen, J., Hartung, H., Perron, H., & Küry, P. (2013) · Annals of Neurology · doi:10.1002/ana.23970 · Cited by 178
Armstrong, R. C., Le, T. Q., Frost, E. E., Borke, R. C., & Vana, A. C. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-19-08574.2002 · Cited by 178
“Further studies are imperative to determine the extent to which regenerative responses can be optimized from the existing oligodendrocyte lineage cell populations that are now being identified in MS lesions (Scolding et al., 1998; Lucchinetti et al., 1999; Chang et al., 2000; Maeda et al., 2001; Solanky et al., 2001;…”
BackgroundUpdates and Advances in Multiple Sclerosis Neurotherapeutics
Amin, M., & Hersh, C. M. (2023) · Neurodegenerative Disease Management · doi:10.2217/nmt-2021-0058 · Cited by 164
“While OPCs are abundant in the CNS and present in chronic MS lesions, remyelination is insufficient, especially in late-stage and progressive MS [149].”
BackgroundMason, J. L., Xuan, S., Dragatsis, I., Efstratiadis, A., & Goldman, J. E. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-20-07710.2003 · Cited by 177
“…presumably because of the depletion of oligodendrocyte progenitors (Lucchinetti et al., 1996; Blakemore and Keirstead, 1999), the loss of axons, the absence of an environment to support progenitor differentiation (Wolswijk, 1998; Chang et al., 2002), or a combination of the above events.”
BackgroundCell-based therapeutic strategies for multiple sclerosis
Scolding, N. J., Pasquini, M., Reingold, S. C., Cohen, J. A., Sclerosis:, I. C. O. C.-B. T. F. M., Atkins, H., Banwell, B., Bar-Or, A., Bebo, B., Bowen, J., et al. (2017) · Brain · doi:10.1093/brain/awx154 · Cited by 170
“Some studies have demonstrated sizable numbers of OPC in some chronically demyelinated lesions (Chang et al., 2002), suggesting that lack of such cells is not the cause of inadequate remyelination in multiple sclerosis.”
BackgroundThe response of NG2-expressing oligodendrocyte progenitors to demyelination in MOG-EAE and MS
Reynolds, R., Dawson, M., Papadopoulos, D., Polito, A., di Bello, I. C., Pham-Dinh, D., & Levine, J. (2002) · Journal of Neurocytology · doi:10.1023/a:1025747832215 · Cited by 175
Wang, Y., Cheng, X., He, Q., Zheng, Y., Kim, D. H., Whittemore, S. R., & Cao, Q. L. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5524-09.2011 · Cited by 173
“These data suggest that manipulation of BMP signaling in the endogenous or grafted NSCs or OPCs may be a useful therapeutic strategy to increase their OL differentiation and remyelination and enhance functional recovery after SCI.”
BackgroundInfluentialmiR-219 Cooperates with miR-338 in Myelination and Promotes Myelin Repair in the CNS
Wang, H., Moyano, A. L., Ma, Z., Deng, Y., Lin, Y., Zhao, C., Zhang, L., Jiang, M., He, X., Ma, Z., et al. (2017) · Developmental Cell · doi:10.1016/j.devcel.2017.03.001 · Cited by 174
“miR-219 Targets Differentiation Inhibitory Pathways and Lingo1 for Remyelination In MS lesions, OPCs are recruited but fail to differentiate into myelinating OLs, suggesting that remyelination is blocked at the differentiation and remyelination stage rather than during OPC recruitment (Chang et al., 2002; Kuhlmann et…”
Activation of sphingosine‐1‐phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration
Novgorodov, A. S., El‐Awani, M., Bielawski, J., Obeid, L. M., & Gudz, T. I. (2007) · The FASEB Journal · doi:10.1096/fj.06-7420com · Cited by 167
Piaton, G., Aigrot, M.-S., Williams, A., Moyon, S., Tepavcevic, V., Moutkine, I., Gras, J., Matho, K. S., Schmitt, A., Soellner, H., et al. (2011) · Brain · doi:10.1093/brain/awr022 · Cited by 163
Inflammation stimulates myelination by transplanted oligodendrocyte precursor cells
Setzu, A., Lathia, J. D., Zhao, C., Wells, K., Rao, M. S., ffrench‐Constant, C., & Franklin, R. J. M. (2006) · Glia · doi:10.1002/glia.20371 · Cited by 172
Weng, Q., Chen, Y., Wang, H., Xu, X., Yang, B., He, Q., Shou, W., Chen, Y., Higashi, Y., van den Berghe, V., et al. (2012) · Neuron · doi:10.1016/j.neuron.2011.12.021 · Cited by 163
“The observation that oligodendrocyte precursor cells (OPCs) are present within demyelinating MS lesions, but fail to differentiate into myelinating oligodendrocytes, suggests that the remyelination process is inhibited at the stage of premyelinating precursors (Chang et al., 2002; Franklin and Ffrench-Constant, 2008).”
Myelin Recovery in Multiple Sclerosis: The Challenge of Remyelination
Podbielska, M., Banik, N., Kurowska, E., & Hogan, E. (2013) · Brain Sciences · doi:10.3390/brainsci3031282 · Cited by 146
“Although in adult human brain remyelination has been demonstrated in MS lesions [149,150], the capacity for regeneration in MS appears limited [151].”
BackgroundLindner, M., Heine, S., Haastert, K., Garde, N., Fokuhl, J., Linsmeier, F., Grothe, C., Baumgärtner, W., & Stangel, M. (2008) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2007.00879.x · Cited by 169
Csf1R inhibition attenuates experimental autoimmune encephalomyelitis and promotes recovery
Nissen, J. C., Thompson, K. K., West, B. L., & Tsirka, S. E. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.05.021 · Cited by 168
“OPCs can differentiate into mature, myelinating oligodendrocytes in lesion sites (Chang et al., 2002; Reynolds et al., 2002; Zawadzka et al., 2010), which is consistent with what we observed at day 21 in the control animals.”
Blocking LINGO-1 as a Therapy to Promote CNS Repair: From Concept to the Clinic
Mi, S., Blake Pepinsky, R., & Cadavid, D. (2013) · CNS Drugs · doi:10.1007/s40263-013-0068-8 · Cited by 167
Thyroid hormone administration enhances remyelination in chronic demyelinating inflammatory disease
Fernandez, M., Giuliani, A., Pirondi, S., D'Intino, G., Giardino, L., Aloe, L., Levi-Montalcini, R., & Calzà, L. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407262101 · Cited by 167
Polydendrocytes: NG2 Cells with Many Roles in Development and Repair of the CNS
Nishiyama, A. (2007) · The Neuroscientist · doi:10.1177/1073858406295586 · Cited by 162
The ERK2 Mitogen-Activated Protein Kinase Regulates the Timing of Oligodendrocyte Differentiation
Fyffe-Maricich, S. L., Karlo, J. C., Landreth, G. E., & Miller, R. H. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3239-10.2011 · Cited by 157
“Latestage OPCs can be found in and around demyelinated lesions in multiple sclerosis patients, suggesting that remyelination by adult OPCs is not inhibited as a result of a lack of mobility or recruitment but rather by an inability of these cells to terminally differentiate (Scolding et al., 1998; Wolswijk, 1998; Chan…”
BackgroundStidworthy, M. F. (2004) · Brain · doi:10.1093/brain/awh217 · Cited by 158
“…contain oligodendrocyte progenitor cells (OPCs) (Scolding et al., 1998; Wolswijk, 1998; Chang et al., 2000; Maeda et al., 2001) or premyelinating oligodendrocytes (Chang et al., 2002), but remain chronically demyelinated without these cells differentiating into stable myelinating oligodendrocytes .”
BackgroundThe biology of CNS remyelination: The key to therapeutic advances
Franklin, R. J. M., & Kotter, M. R. (2008) · Journal of Neurology · doi:10.1007/s00415-008-1004-6 · Cited by 160
“These experimental findings are consistent with histopathological observations in multiple sclerosis [3, 27], which have shown that non-remyelinating lesions contain an abundance of oligodendrocyte lineage cells but that these fail to undergo complete differentiation into functional oligodendrocytes.”
ResultVoskuhl, R. R., Itoh, N., Tassoni, A., Matsukawa, M. A., Ren, E., Tse, V., Jang, E., Suen, T. T., & Itoh, Y. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821306116 · Cited by 162
“Insufficient remyelination in MS is related in part to the inability of oligodendrocyte precursor cells (OPCs) to differentiate into mature myelinating oligodendrocytes (3, 4).”
BackgroundThe translational biology of remyelination: past, present, and future
Franklin, R. J. M., & Gallo, V. (2014) · Glia · doi:10.1002/glia.22622 · Cited by 162
“Importantly, 1906 Volume 62, No. 11 expression of the marker proteins that characterize OPCs in the normal and pathological rodent brain has also been revealed in MS tissue (Arnett et al., 2004; Chang et al., 2002; Nait-Oumesmar et al., 2007).”
BackgroundAdvanced MRI and staging of multiple sclerosis lesions
Absinta, M., Sati, P., & Reich, D. S. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.59 · Cited by 154
Oligodendroglia and Myelin in Neurodegenerative Diseases: More Than Just Bystanders?
Ettle, B., Schlachetzki, J. C. M., & Winkler, J. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9205-3 · Cited by 160
“Considering that axonal damage frequently and predominantly occurs within demyelinated plaques, these findings strongly indicate that a deficiency in both OPC maturation and remyelination contributes to axonal and finally neuronal degeneration in MS [74, 75].”
BackgroundRemyelination In Multiple Sclerosis
Chari, D. M. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(07)79026-8 · Cited by 119
“The authors concluded that remyelination failure could not be accounted for either by the absence of OPCs or their failure to generate oligodendrocytes, but instead suggested that demyelinated axons were themselves no longer receptive to remyelination (Chang et al., 2002).”
BackgroundMurtie, J. C., Zhou, Y.-X., Le, T. Q., Vana, A. C., & Armstrong, R. C. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.12.006 · Cited by 157
“Immature oligodendrocyte lineage cells (OLCs) persist in the adult rodent and human CNS and may have the potential to enhance remyelination if directed to differentiate into oligodendrocytes (Armstrong et al., 1992; Chang et al., 2002; Goldman, 2003).”
BackgroundThe role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis
Mallucci, G., Peruzzotti-Jametti, L., Bernstock, J. D., & Pluchino, S. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.02.003 · Cited by 145
“…on patients with progressive MS have revealed that the density of OPCs and premyelinating oligodendrocytes is not decreased in cortical lesions (Chang et al., 2002), and this is likely due to a more permissive microenvironment for OPCs within the cortex (e.g. less extracellular matrix…”
Flygt, J., Djupsjö, A., Lenne, F., & Marklund, N. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12179 · Cited by 163
“thick sections were used to enable the detection of pre-myelinating OLs (Chang et al., 2002).”
MethodPedre, X., Mastronardi, F., Bruck, W., López-Rodas, G., Kuhlmann, T., & Casaccia, P. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.4507-10.2011 · Cited by 145
Oligodendrocytes and the early multiple sclerosis lesion
Prineas, J. W., & Parratt, J. D. E. (2012) · Annals of Neurology · doi:10.1002/ana.23634 · Cited by 149
Zamvil, S. S., & Steinman, L. (2003) · Neuron · doi:10.1016/s0896-6273(03)00326-x · Cited by 149
“…including its terminal components, the “membrane attack complex,” are also detected along nerve they appeared to interact with dystrophic naked axons but were unable to remyelinate them (Chang et al., 2002).fibers in active demyelinating lesions and periplaque white matter (Prineas et al., 2001).”
BackgroundLi, Z., He, Y., Fan, S., & Sun, B. (2015) · Neuroscience Bulletin · doi:10.1007/s12264-015-1555-3 · Cited by 157
Hunter, S. F., Bowen, J. D., & Reder, A. T. (2015) · CNS Drugs · doi:10.1007/s40263-015-0297-0 · Cited by 161
“In chronic demyelinated lesions, significant myelin repair is lacking, despite an abundance of OPCs in the region; this may be caused by arrested oligodendroglial differentiation [40, 45–47].”
BackgroundLi, C., Xiao, L., Liu, X., Yang, W., Shen, W., Hu, C., Yang, G., & He, C. (2013) · Glia · doi:10.1002/glia.22469 · Cited by 138
“…therapeutic approaches for demyelinating diseases, specially given that OPCs differentiation impairment has been demonstrated to be the main cause of remyelination failure (Billiards et al., 2008; Chang et al., 2000, 2002; Nave, 2010; Segovia et al., 2008; Taveggia et al., 2010; Wolswijk 2000).”
BackgroundLesion stage-dependent causes for impaired remyelination in MS
Heß, K., Starost, L., Kieran, N. W., Thomas, C., Vincenten, M. C. J., Antel, J., Martino, G., Huitinga, I., Healy, L., & Kuhlmann, T. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02189-9 · Cited by 137
Zhao, C., Li, W.-W., & Franklin, R. J. M. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.06.008 · Cited by 142
Olig1 Function Is Required for Oligodendrocyte Differentiation in the Mouse Brain
Dai, J., Bercury, K. K., Ahrendsen, J. T., & Macklin, W. B. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.4962-14.2015 · Cited by 128
“…block in demyelinated lesions of adult Olig1-null mice resembles MS lesions where OPCs are present but many either fail to differentiate (Chang et al., 2000; Kuhlmann et al., 2008) or are blocked as premyelinating oligodendrocytes unable to differentiate further (Chang et al., 2002).”
BackgroundGhaiad, H. R., Nooh, M. M., El‐Sawalhi, M. M., & Shaheen, A. A. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9891-5 · Cited by 152
Interleukin-11 Potentiates Oligodendrocyte Survival and Maturation, and Myelin Formation
Zhang, Y., Taveggia, C., Melendez-Vasquez, C., Einheber, S., Raine, C. S., Salzer, J. L., Brosnan, C. F., & John, G. R. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2289-06.2006 · Cited by 138
“, 2000), and those in which OPCs are present but unable to complete the myelination program (Wolswijk, 1998; Chang et al., 2002).”
BackgroundNeuronal activity in vivo enhances functional myelin repair
Ortiz, F. C., Habermacher, C., Graciarena, M., Houry, P.-Y., Nishiyama, A., Oumesmar, B. N., & Angulo, M. C. (2019) · JCI Insight · doi:10.1172/jci.insight.123434 · Cited by 133
“are poorly receptive for remyelination (2, 3).”
Oestrogen receptor β ligand: a novel treatment to enhance endogenous functional remyelination
Crawford, D. K., Mangiardi, M., Song, B., Patel, R., Du, S., Sofroniew, M. V., Voskuhl, R. R., & Tiwari-Woodruff, S. K. (2010) · Brain · doi:10.1093/brain/awq237 · Cited by 134
Multiple sclerosis: molecular pathogenesis and therapeutic intervention
Boutitah-Benyaich, I., Eixarch, H., Villacieros‐Álvarez, J., Hervera, A., Cobo‐Calvo, Á., Montalbán, X., & Espejo, C. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02415-4 · Cited by 160
Leech, S., Kirk, J., Plumb, J., & McQuaid, S. (2007) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2006.00781.x · Cited by 137
Lindner, M., Fokuhl, J., Linsmeier, F., Trebst, C., & Stangel, M. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.02.004 · Cited by 136
Cheng, X., Wang, Y., He, Q., Qiu, M., Whittemore, S. R., & Cao, Q. (2007) · Stem Cells · doi:10.1634/stemcells.2007-0284 · Cited by 131
The complex world of oligodendroglial differentiation inhibitors
Kremer, D., Aktas, O., Hartung, H., & Küry, P. (2011) · Annals of Neurology · doi:10.1002/ana.22415 · Cited by 131
He, D., Wang, J., Lu, Y., Deng, Y., Zhao, C., Xu, L., Chen, Y., Hu, Y.-C., Zhou, W., & Lu, Q. R. (2017) · Neuron · doi:10.1016/j.neuron.2016.11.044 · Cited by 133
Rittchen, S., Boyd, A., Burns, A., Park, J., Fahmy, T. M., Metcalfe, S., & Williams, A. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.03.044 · Cited by 131
“However, in many MS lesions there appears to be a critical block in the maturation of OPCs to myelinating OD [4,5] and factors that improve OPC maturation improve remyelination in animal models of demyelination.”
BackgroundInhibition of CNS Remyelination by the Presence of Semaphorin 3A
Syed, Y. A., Hand, E., Möbius, W., Zhao, C., Hofer, M., Nave, K. A., & Kotter, M. R. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.4930-10.2011 · Cited by 134
Choi, I. Y., Lee, C., & Longo, V. D. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.01.042 · Cited by 133
Neely, S. A., Williamson, J. M., Klingseisen, A., Zoupi, L., Early, J. J., Williams, A., & Lyons, D. A. (2022) · Nature Neuroscience · doi:10.1038/s41593-021-01009-x · Cited by 132
The role of TGF-β superfamily signaling in neurological disorders
Kashima, R., & Hata, A. (2018) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmx124 · Cited by 126
Penderis, J., Shields, S. A., & Franklin, R. J. M. (2003) · Brain · doi:10.1093/brain/awg126 · Cited by 129
“…signalling pathway (Wang et al., 1998; John et al., 2002) and PSA-NCAM (polysialylated neural cell adhesion molecule) (Charles et al., 2002), or due to changes in the properties of demyelinated axons that render them incapable of being remyelinated (Chang et al., 2002) is not fully resolved.”
BackgroundThe emerging role of microRNAs in multiple sclerosis
Junker, A., Hohlfeld, R., & Meinl, E. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.179 · Cited by 129
Netrin 1 and Dcc regulate oligodendrocyte process branching and membrane extension via Fyn and RhoA
Rajasekharan, S., Baker, K. A., Horn, K. E., Jarjour, A. A., Antel, J. P., & Kennedy, T. E. (2009) · Development · doi:10.1242/dev.018234 · Cited by 123
“Interestingly, many oligodendroglial cells detected in multiple sclerosis lesions appear to have differentiated, but remain unable to elaborate myelin (Chang et al., 2002).”
BackgroundDulamea, A. O. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-47861-6_7 · Cited by 128
Neurodegeneration and demyelination in multiple sclerosis
Garton, T. P., Gadani, S. P., Gill, A. J., & Calabresi, P. A. (2024) · Neuron · doi:10.1016/j.neuron.2024.05.025 · Cited by 144
Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis
Girolamo, F., Coppola, C., Ribatti, D., & Trojano, M. (2014) · Acta Neuropathologica Communications · doi:10.1186/preaccept-1363293028126438 · Cited by 126
“OPCs are also widely distributed in adult human brain and MS lesions [148] and are guided to repair demyelinated axons [149].”
BackgroundLaursen, L. S., Chan, C. W., & ffrench-Constant, C. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201007014 · Cited by 118
Jeffries, M. A., Urbanek, K., Torres, L., Wendell, S. G., Rubio, M. E., & Fyffe-Maricich, S. L. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.1444-16.2016 · Cited by 118
“Because differentiating OPCs often become arrested at premyelinating stages during the progressive phase of demyelinating diseases such as multiple sclerosis (Chang et al., 2002; Sim et al., 2002) and the pool of OPCs present in the adult brain is relatively small, it is important to investigate whether the large pool…”
BackgroundRemyelinating strategies for the treatment of multiple sclerosis
Stangel, M., & Hartung, H.-P. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00105-3 · Cited by 126
Endogenous cell repair of chronic demyelination
Armstrong, R. C., Le, T. Q., Flint, N. C., Vana, A. C., & Zhou, Y.-X. (2006) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000205142.08716.7e · Cited by 125
“Similarly, immature oligodendrocyte lineage cells persist in the adult human CNS and may proliferate to increase in number within and near MS lesions (8, 9) .”
BackgroundLassmann, H. (2011) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2011.01189.x · Cited by 120
Su, Z., Yuan, Y., Chen, J., Zhu, Y., Qiu, Y., Zhu, F., Huang, A., & He, C. (2011) · Journal of Neurotrauma · doi:10.1089/neu.2010.1597 · Cited by 118
“However, OPCs proliferating and accumulating around demyelinated lesions usually fail to convert into myelin-producing cells and do not remyelinate affected axons, leaving them vulnerable to progressive axonal degeneration (Chang et al., 2002; Franklin, 2002).”
FGF-2 and Anosmin-1 Are Selectively Expressed in Different Types of Multiple Sclerosis Lesions
Clemente, D., Ortega, M. C., Arenzana, F. J., & de Castro, F. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.1158-11.2011 · Cited by 124
“Plaques present in brain tissue samples from 10 human MS patients were classified (Table 1) according to previously described methods (Trapp et al., 1999; Chang et al., 2002, 2008; Benito et al., 2007; Koning et al., 2007; Breij et al., 2008; Young et al., 2008).”
MethodWilson, H., Scolding, N. J., & Raine, C. S. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.04.014 · Cited by 141
Parallel states of pathological Wnt signaling in neonatal brain injury and colon cancer
Fancy, S. P. J., Harrington, E. P., Baranzini, S. E., Silbereis, J. C., Shiow, L. R., Yuen, T. J., Huang, E. J., Lomvardas, S., & Rowitch, D. H. (2014) · Nature Neuroscience · doi:10.1038/nn.3676 · Cited by 115
Myelin regulatory factor drives remyelination in multiple sclerosis
Duncan, G. J., Plemel, J. R., Assinck, P., Manesh, S. B., Muir, F. G. W., Hirata, R., Berson, M., Liu, J., Wegner, M., Emery, B., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1741-7 · Cited by 114
“1 3 that a population of myelin proteolipid protein expressing (PLP+) oligodendrocytes fails to radially wrap axons and successfully remyelinate in the majority of chronically demyelinated lesions [7].”
BackgroundTransplanted Neural Precursors Enhance Host Brain-Derived Myelin Regeneration
Einstein, O., Friedman‐Levi, Y., Grigoriadis, N., & Ben‐Hur, T. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.3364-09.2009 · Cited by 123
“In many MS lesions immature OPCs and premyelinating oligodendrocytes are present in relatively normal density but do not remyelinate efficiently (Scolding et al., 1998; Wolswijk, 1998; Maeda et al., 2001; Chang et al., 2002).”
BackgroundThe Pathology of MS: New Insights and Potential Clinical Applications
Pittock, S. J., & Lucchinetti, C. F. (2007) · The Neurologist · doi:10.1097/01.nrl.0000253065.31662.37 · Cited by 116
“In turn, axonal pathology may limit remyelination due to the limited axonal trophic support to myelin sheaths and oligodendrocytes.(28) Inflammation in Multiple Sclerosis Pathology”
BackgroundA recombinant human IgM promotes myelin repair after a single, very low dose
Warrington, A. E., Bieber, A. J., Ćirić, B., Pease, L. R., Keulen, V. P. V., & Rodriguez, M. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21217 · Cited by 118
“However, remyelination is often quite limited, suggesting that the numerous oligodendrocyte progenitors (OLPs) remaining within and adjacent to MS lesions (Maeda et al., 2001; Chang et al., 2002; Wolswijk, 2002) are blocked at some point on the path to myelination.”
BackgroundAchievements and obstacles of remyelinating therapies in multiple sclerosis
Stangel, M., Kuhlmann, T., Matthews, P. M., & Kilpatrick, T. J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.139 · Cited by 118
Somatodendritic Expression of JAM2 Inhibits Oligodendrocyte Myelination
Redmond, S. A., Mei, F., Eshed-Eisenbach, Y., Osso, L. A., Leshkowitz, D., Shen, Y.-A. A., Kay, J. N., Aurrand-Lions, M., Lyons, D. A., Peles, E., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.07.021 · Cited by 110
“However, it has also been observed in human postmortem MS lesions that differentiated oligodendrocytes are present, but fail to remyelinate axons (Chang et al., 2002).”
Multimodal Enhancement of Remyelination by Exercise with a Pivotal Role for Oligodendroglial PGC1α
Jensen, S. K., Michaels, N. J., Ilyntskyy, S., Keough, M. B., Kovalchuk, O., & Yong, V. W. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.060 · Cited by 105
Tepavčević, V., & Lubetzki, C. (2022) · Brain · doi:10.1093/brain/awac307 · Cited by 108
Canonical Wnt signaling in the oligodendroglial lineage-puzzles remain
Guo, F., Lang, J., Sohn, J., Hammond, E., Chang, M., & Pleasure, D. (2015) · Glia · doi:10.1002/glia.22813 · Cited by 106
Giraudon, P., Vincent, P., Vuaillat, C., Verlaeten, O., Cartier, L., Marie-Cardine, A., Mutin, M., Bensussan, A., Belin, M.-F., & Boumsell, L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.2.1246 · Cited by 112
“The present data together with 1) the abundant expression of CD100 by activated T cells (7, 10), 2) the elevated expression of metalloproteinases within the CNS of patients suffering neuroinflammatory demyelination (23, 40), and 3) the gradual reduction in the size of the oligodendrocyte population, but the sustained…”
ResultMiller, R. H., & Mi, S. (2007) · Nature Neuroscience · doi:10.1038/nn1995 · Cited by 125
Köfalvi, A. (2007) · Springer eBooks · doi:10.1007/978-0-387-74349-3 · Cited by 116
Wang, Y., Imitola, J., Rasmussen, S., O'Connor, K. C., & Khoury, S. J. (2008) · Annals of Neurology · doi:10.1002/ana.21457 · Cited by 109
“Premyelinating oligodendrocytes have been described in MS and EAE lesions.(1,3) However, oligodendrocyte precursor cell (OPC) differentiation and functional remyelination is lacking in MS or EAE lesions, unlike what happens in neurotoxin-induced demyelination.”
BackgroundImmunomodulation in multiple sclerosis: from immunosuppression to neuroprotection
Neuhaus, O., Archelos, J. J., & Hartung, H. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00028-2 · Cited by 111
Interferon‐γ inhibits cell cycle exit in differentiating oligodendrocyte progenitor cells
Chew, L., King, W. C., Kennedy, A., & Gallo, V. (2005) · Glia · doi:10.1002/glia.20232 · Cited by 107
“Several investigators have reported an abundance of OPCs associated with lesions (Wolswijk, 1998), identified by immunostaining with PDGF receptor-a (Maeda et al., 2001) or with the sulfated proteoglycan NG2 (Chang et al., 2002).”
BackgroundImaging correlates of decreased axonal Na + /K + ATPase in chronic multiple sclerosis lesions
Young, E. A., Fowler, C. D., Kidd, G. J., Chang, A., Rudick, R., Fisher, E., & Trapp, B. D. (2008) · Annals of Neurology · doi:10.1002/ana.21381 · Cited by 111
“Sections were stained for myelin proteins and major histocompatability complex class II, and classified as acute, chronic active or chronic inactive, as described previously.(19) Three acute and 36 chronic lesions were identified.”
MethodSelf-citationDigestion products of the PH20 hyaluronidase inhibit remyelination
Preston, M., Gong, X., Su, W., Matsumoto, S. G., Banine, F., Winkler, C., Foster, S., Xing, R., Struve, J., Dean, J., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23788 · Cited by 107
Plemel, J. R., Manesh, S. B., Sparling, J. S., & Tetzlaff, W. (2013) · Glia · doi:10.1002/glia.22535 · Cited by 107
“…Maturation September 2013 1481 1482 Volume 61, No. 9 of a quiescent population of OPCs at sites of chronic demyelination highlights the need to promote OPC differentiation/ maturation (Chang et al., 2000, 2002; Kuhlmann et al., 2008), e.g., by blocking inhibitors of differentiation/maturation.”
BackgroundAxon‐oligodendrocyte interactions during developmental myelination, demyelination and repair
Piaton, G., Gould, R. M., & Lubetzki, C. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06831.x · Cited by 102
“Evidence for remyelination has first been found in roughly 40% of MS white matter lesions, often incomplete and restricted to the lesion edge (Prineas and Connell 1979; Chang et al. 2002; Barkhof et al. 2003).”
BackgroundMolecular mechanisms of axonal damage in inflammatory central nervous system diseases
Neumann, H. (2003) · Current Opinion in Neurology · doi:10.1097/00019052-200306000-00004 · Cited by 108
Interaction of mTOR and Erk1/2 signaling to regulate oligodendrocyte differentiation
Dai, J., Bercury, K. K., & Macklin, W. B. (2014) · Glia · doi:10.1002/glia.22729 · Cited by 114
“…progenitor cells (OPCs) are abundant in chronic MS lesion sites, which, along with other clinical observations, strongly indicates that inefficient remyelination in MS largely results from an inability of OPCs to differentiate to myelinating oligodendrocytes (Chang et al., 2000, 2002).”
BackgroundFitzner, D., & Simons, M. (2010) · Current Neuropharmacology · doi:10.2174/157015910792246218 · Cited by 103
“The reasons why remyelination is impaired in MS are not complete understood, but one likely mechanism is the inhibition of oligodendrocyte precursor cells within chronic MS plaques [118, 119].”
BackgroundMetabolomics-based discovery of a metabolite that enhances oligodendrocyte maturation
Beyer, B. A., Fang, M., Sadrian, B., Montenegro-Burke, J. R., Plaisted, W. C., Kok, B. P., Sáez, E., Kondo, T., Siuzdak, G. E., & Lairson, L. L. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2517 · Cited by 112
Integrin-mediated axoglial interactions initiate myelination in the central nervous system
Câmara, J., Wang, Z., Nunes-Fonseca, C., Friedman, H. C., Grove, M., Sherman, D. L., Komiyama, N. H., Grant, S. G., Brophy, P. J., Peterson, A., et al. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200807010 · Cited by 96
Phillips, J. T., Giovannoni, G., LUBLIN, F. D., O'Connor, P. W., Polman, C. H., Willoughby, E., Aschenbach, W. G., Pace, A., Hyde, R., & Munschauer, F. E. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458511399611 · Cited by 111
Ziabreva, I., Campbell, G., Rist, J., Zambonin, J., Rorbach, J., Wydro, M. M., Lassmann, H., Franklin, R. J. M., & Mahad, D. (2010) · Glia · doi:10.1002/glia.21052 · Cited by 102
“A block in OPC differentiation has also been reported in MS (Chang et al., 2000, 2002; Kuhlmann et al., 2008; Wolswijk, 1998).”
Metadata
- Authors
- Chang, A., Tourtellotte, W. W., Rudick, R., & Trapp, B. D.
- Affiliations
- Cleveland Clinic (US)
- VA West Los Angeles Medical Center (US)
- Cleveland Clinic Research (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-01-17
- Volume
- 346
- Issue
- 3
- Pages
- 165-173
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2058358434
- Cited by
- 991
- References
- 39
- Citations by year
- 2026: 19 · 2025: 25 · 2024: 42 · 2023: 38 · 2022: 32 · 2021: 34 · 2020: 36 · 2019: 57 · 2018: 43 · 2017: 52 · 2016: 44 · 2015: 55 · 2014: 44 · 2013: 50 · 2012: 40
- FWCI
- 26.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Neurological Disorders and Stroke (R01 NS35058, P01NS038667, R01NS035058, P01-NS-38667)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Keywords
- multiple sclerosis, remyelination, chronic lesions, demyelinated axons, oligodendrocyte precursor cells, disease duration
- MeSH terms
- Chondroitin Sulfate Proteoglycan 4, Adult, Aged, Antigens, Axons, Brain, Brain Chemistry, Female, Humans, Male, Middle Aged, Multiple Sclerosis, Nerve Fibers, Myelinated, Oligodendroglia, Proteoglycans, Stem Cells, Microscopy, Confocal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.